Illumina Newsroom

This D.R. Horton Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday

Benzinga21:35

Illumina Analyst Ratings

Benzinga20:22 · Ratings

Express News | Illumina Inc : Citigroup Cuts to Neutral From Buy

Breakings20:00

Citi Downgrades Illumina(ILMN.US) to Hold Rating, Cuts Target Price to $165

Futu News19:33 · Ratings

RBC Trims Price Target on Illumina to $252 From $254, Keeps Outperform Rating

MT NewswiresDec 9 20:05 · Ratings

Illumina Granted Access to Synaffix's Metal-Free Click Chemistry Technology

MT NewswiresDec 4 19:12

Illumina To Webcast Upcoming Investor Conference

IlluminaDec 4 13:00

Illumina Inc. Stock Outperforms Competitors On Strong Trading Day

MarketWatchDec 3 06:27

Trump's Unusual Pick for NIH Director May Be a Win for These Stocks -- Barrons.com

Barron'sNov 28 03:26

Is Illumina, Inc. (NASDAQ:ILMN) Potentially Undervalued?

Simply Wall StNov 26 22:59

Illumina, Inc. (ILMN): Constrained Spending in Pharmaceutical Industry Pressures Shares Despite Strong Niche Position

Yahoo FinanceNov 26 06:41

MYGN Stock Up on Integration of HRD Platform Into Illumina's TSO 500 V2

Zacks Nov 25 19:05

Myriad Genetics Announces The Incorporation Of Its HRD Platform In Illumina's Updated Gene Panel Assay

BenzingaNov 21 05:33

Myriad Genetics Announces Incorporation of Its Proprietary HRD Platform in Illumina's Updated Comprehensive Gene Panel Assay, TruSight Oncology 500 V2

Globe NewswireNov 21 05:30

If RFK Jr. Cuts Science Funding, These Instrument Makers May Suffer -- Barrons.com

Barron'sNov 21 04:29

Illumina, Inc. (ILMN) CFO Ankur Dhingra Hosts Wolfe Research 2024 Healthcare Conference (Transcript)

Earnings Call TranscriptsNov 21 03:09

Because Minna announced the expansion of the TruSight Oncology product line.

The latest solution will be unveiled at the annual meeting of the Molecular Pathology Association to achieve a comprehensive mutation analysis of tumors. Research and sharing led by Illumina customers will provide the latest evidence and related content for tumor analysis. San Diego, California, USA, November 20, 2024 / PRNewswire / -- Illumina Inc. (NASDAQ: ILMN), a leader in global DNA sequencing and chip technology, today announced the launch of a new version of its flagship cancer research testing product, TruSight Oncology 500 v2 (TSO 500 v2), for

PR NewswireNov 20 10:00

Express News | Illumina Inc: Trusight Oncology 500 V2 Assay Is Currently Under Development, Global Release Planned for Mid-2025

BreakingsNov 19 22:16

Express News | Illumina Announces Expansion of Trusight Oncology Portfolio

BreakingsNov 19 22:15

Illumina Announces Expansion of TruSight Oncology Portfolio

PR NewswireNov 19 22:15